HOUSTON, Jan. 17 /PRNewswire/ -- Agennix Incorporated announced today that the U.S.

HOUSTON, June 4 /PRNewswire/ -- Agennix Incorporated today announced results from a fourth positive Phase II trial with its lead molecule talactoferrin alfa, an immunomodulatory protein with a novel mechanism of action.

HOUSTON, June 13 /PRNewswire/ -- Agennix Incorporated announced results from a randomized, placebo-controlled, NIH-sponsored, multi-center Phase II clinical trial evaluating topical talactoferrin alfa (talactoferrin) in diabetic neuropathic ulcers.

HOUSTON, April 19 /PRNewswire/ -- Agennix Incorporated announced results from a double-blind, randomized, placebo-controlled, multi-center Phase II clinical trial evaluating oral talactoferrin alfa (talactoferrin), the Company's proprietary recombinant human lactoferrin.